Treatment of diabetic macular edema
Diabetologe, ISSN: 1860-9724, Vol: 14, Issue: 8, Page: 577-589
2018
- 5Citations
- 24Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Background: Diabetic macular edema (DME) is a common cause of diabetes-related visual impairment that also affects patients of working age. Laser treatment has been the gold standard of DME treatment for decades. The introduction of intravitreal injection therapies, e. g. anti-VEGF therapy, has widened the range of treatment options. This allows more individualized DME therapy and improves the prognosis for vision. Objectives: This article aims to provide a short overview of current therapy options and their relevance in DME treatment based on recent studies and treatment recommendations. Results: VEGF-Inhibitors represent a first-line treatment and are superior to laser treatment when DME affects the fovea. In addition to ranibizumab and aflibercept, bevacizumab is used off-label. High treatment frequencies with an average of seven to nine injections in the 1st year and monthly controls, if possible using optical coherence tomography, are crucial. The number of injections required decreases thereafter. The gain in visual acuity of on average two to three lines demonstrated in studies is usually not achieved in real life due to under-treatment. Intravitreal steroids provide longer treatment effects, but are second choice due to local side effects, mainly cataract and glaucoma. Laser therapy remains an option (1st choice in extrafoveal DME). In special cases, vitrectomy may be indicated. Conclusions: Modern DME treatment permits individualized therapies based on multimodal diagnostics while taking the patient’s individual situation and wishes into account. However, in order to make effective use of these opportunities , early diagnosis (screening), adequate patient motivation, and appropriate risk factor adjustment are required.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85055507658&origin=inward; http://dx.doi.org/10.1007/s11428-018-0404-1; http://link.springer.com/10.1007/s11428-018-0404-1; http://link.springer.com/content/pdf/10.1007/s11428-018-0404-1.pdf; http://link.springer.com/article/10.1007/s11428-018-0404-1/fulltext.html; https://dx.doi.org/10.1007/s11428-018-0404-1; https://link.springer.com/article/10.1007/s11428-018-0404-1
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know